For the last 10 years, the only effective treatment for hypophosphatasia (HPP) has been an enzyme replacement therapy that must be delivered by injection three-to-six times each week.

“We are pleased to welcome Jesse to the Axogen team," said Michael Dale, Chief Executive Officer, and Director, Axogen. "His extensive experience in regulatory strategy and deep understanding of the ...

Axogen (AXGN) announced the appointment of Jesse Bishop as Vice President of Regulatory Affairs. Bishop will report to Michael Dale, President, ...

The World Health Organization (WHO) congratulates Niger for having met the criteria for onchocerciasis elimination, making it ...